Get the Stockscreener App
6.82
10.00%
0.62
After Hours:
6.65
-0.17
-2.49%
Dbv Technologies Adr stock is traded at $6.82, with a volume of 647.84K.
It is up +10.00% in the last 24 hours and up +53.26% over the past month.
See More
Previous Close:
$6.20
Open:
$6
24h Volume:
647.84K
Relative Volume:
1.63
Market Cap:
$80.22M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-6.4952
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+52.91%
1M Performance:
+53.26%
6M Performance:
+94.86%
1Y Performance:
-8.96%
1-Day Range:
$5.75
$7.28
1-Week Range:
$3.91
$7.28
52-Week Range:
$2.2045
$8.318
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
6.82 | 80.22M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 33.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com - Defense World
European ADRs See Mixed Results With Biopharma Leading Gains - Finimize
Why DBV Technologies (DBVT) Stock Is Skyrocketing - Benzinga
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' - Benzinga
DBV Technologies announces up to $307M financing to advance Viaskin Peanut program - MSN
DBV Technologies Announces Financing of up to $306.9 - GlobeNewswire
Major Breakthrough: $306.9M Funding Powers Revolutionary Peanut Allergy Patch to FDA Finish Line - Stock Titan
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
DBV Technologies faces cash shortage, stock drops By Investing.com - Investing.com South Africa
DBV Technologies faces cash shortage, stock drops - Investing.com
DBV Technologies Secures Agreement with FDA on Safety - GlobeNewswire
Major FDA Breakthrough: DBV's Peanut Allergy Treatment Path Accelerates Despite Cash Concerns - Stock Titan
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials By Investing.com - Investing.com South Africa
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials - Investing.com
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
JMP reiterates DBV Technologies stock with $10 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
DBV Technologies (DBVT) to Release Earnings on Thursday - Defense World
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - The Manila Times
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Can This Peanut Patch Help Children Safely Eat 3-4 Peanuts? New 5-Year Data Reveals Promising Results - StockTitan
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading - TradingView
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces funding hurdles - Investing.com India
DBV Technologies' SWOT analysis: peanut allergy patch stock faces funding hurdles - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) vs. Allogene Therapeutics (NASDAQ:ALLO) Critical Contrast - Defense World
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com - MarketBeat
DBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - TradingView
DBV Technologies stock holds firm with $10 target from JMP By Investing.com - Investing.com South Africa
DBV Technologies stock holds firm with $10 target from JMP - Investing.com India
DBV Technologies (NASDAQ:DBVT) Shares Cross Above Fifty Day Moving Average – Time to Sell? - Defense World
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
| Mohideen Pharis | Chief Medical Officer |
May 24 '24 |
Sale |
1.36 |
660 |
898 |
81,152 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '24 |
Sale |
1.38 |
382 |
527 |
81,812 |
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):